Grifols To Launch A Takeover Bid For Germany’s Biotest At €1.6 Bn
Grifols and Tiancheng Pharma, the main shareholder of Germany’s Biotest, have agreed that Grifols will buy Biotest with the aim of increasing its plasma collection capacity. Tiancheng Pharma owns 89.9% of Biotest’s ordinary shares and 1.1% of the preferred shares. The consideration of €1.6 Bn for the 100% of Biotest will be paid in cash and represents a premium of 23%.
